Nalazite se na CroRIS probnoj okolini. Ovdje evidentirani podaci neće biti pohranjeni u Informacijskom sustavu znanosti RH. Ako je ovo greška, CroRIS produkcijskoj okolini moguće je pristupi putem poveznice www.croris.hr
izvor podataka: crosbi !

T142 Role of kallikrein 6 (KLK6) in the differential diagnosis of dementia (CROSBI ID 601705)

Prilog sa skupa u zborniku | sažetak izlaganja sa skupa

Dukić, Lora ; Šimundić, Ana-Maria ; Martinić- Popović, Irena ; Diamandis, Eleftherios P ; Begčević Ilijana T142 Role of kallikrein 6 (KLK6) in the differential diagnosis of dementia // Biochim Clin. 2013. str. S362-S362

Podaci o odgovornosti

Dukić, Lora ; Šimundić, Ana-Maria ; Martinić- Popović, Irena ; Diamandis, Eleftherios P ; Begčević Ilijana

engleski

T142 Role of kallikrein 6 (KLK6) in the differential diagnosis of dementia

BACKGROUND: Dementia is global loss of cognitive functions. Based on the pathobiochemical process, there are two major types of dementia: Alzheimer's disease (AD) and vascular dementia (VAD). The prodromal phase of dementia is defined as mild cognitive impairment (MCI). Proper recognition of the dementia etiology is necessary in order to assure early and effecitive treatment. Human kallikrein 6 (KLK6) is a serine protease highly expressed in brain. The aim of this pilot study was to evaluate the role of KLK6 as a serum biomarker for differential diagnosis of dementia. METHODS: We recruited 28 patients with AD (18 females, range 56-84 years) and 27 patients with VAD (13 females, range 58-89 years) from the University Department of Neurology. The control group consisted of 11 cognitively healthy individuals (9 females, range 57-78 years) and 14 individuals diagnosed with MCI (10 females, range 53-79 years). The concentration of KLK6 was measured by an ELISA method. RESULTS: Mann-Whitney test for independent samples was used for statistical analysis of the data. A significant difference in KLK6 concentration was found between AD (median 3.20 ; range 2.83-3.63 ng/mL) vs. VAD (median 2.54 ; range 2.25-2.86 ng/mL) (P=0.004) patients and in AD (3.20 ; 2.83-3.63 ng/mL) vs. MCI group (2.61 ; 2.36-2.74 ng/mL) (P=0.0145). KLK6 values were significantly higher in the control group of cognitively healthy individuals (2.97 ; 2.64-4.38 ng/mL) vs. VAD patients (2.54 ; 2.25-2.86 ng/mL) (P=0.0478). CONCLUSIONS: AD patients display significantly higher serum concentration of KLK6 than VAD patients. More extensive studies are needed to asses clinical utility of KLK6 in the differential diagnosis of dementia.

Alzheimer's disease ; vascular dementia ; kallikrein 6

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

Podaci o prilogu

S362-S362.

2013.

objavljeno

Podaci o matičnoj publikaciji

Biochim Clin

Podaci o skupu

EUROMEDLAB 2013

poster

19.05.2013-23.05.2013

Milano, Italija

Povezanost rada

Kliničke medicinske znanosti